A Phase 2 Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis (MS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VSN 16R (Primary)
Indications Muscle spasticity
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Canbex Therapeutics

Most Recent Events

28 Feb 2018 Status changed from recruiting to completed.
30 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
30 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight